John Cini
Founder at SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Net worth: 3 221 $ as of 2024-04-29
Profile
John K.
Cini is the founder of Sonnet BioTherapeutics, Inc. (founded in 2015) and Sonnet BioTherapeutics Holdings, Inc. (founded in 2011).
At Sonnet BioTherapeutics, Inc., he holds the title of Chief Scientific Officer since 2015, and at Sonnet BioTherapeutics Holdings, Inc., he holds the title of Chief Scientific Officer since 2020.
Dr. Cini's former jobs include Executive Director at Medarex, Inc. and Vice President-Discovery & Development Sciences at Outlook Therapeutics, Inc. (2011-2015).
Dr. Cini earned a doctorate degree from the University of North Texas.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-12-10 | 1,830 ( 0.06% ) | 3 221 $ | 2024-04-29 |
John Cini active positions
Companies | Position | Start |
---|---|---|
SONNET BIOTHERAPEUTICS HOLDINGS, INC. | Founder | 2010-12-31 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Founder | 2014-12-31 |
Former positions of John Cini
Companies | Position | End |
---|---|---|
OUTLOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 2015-03-31 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Director/Board Member | - |
Training of John Cini
University of North Texas | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
OUTLOOK THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Health Technology |
Sonnet BioTherapeutics Holdings, Inc. | |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
- Stock Market
- Insiders
- John Cini